Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $9.00.

Aptose Biosciences Stock Up 1.3 %

Aptose Biosciences stock opened at $0.41 on Thursday. The firm has a market capitalization of $7.34 million, a PE ratio of -0.07 and a beta of 1.25. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $3.32. The firm’s 50-day simple moving average is $0.45 and its 200 day simple moving average is $0.89.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.15. On average, research analysts expect that Aptose Biosciences will post -2.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.